ALLR today
$0.91-$0.02 (-2.30%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourExpanding
1 hourLeaning Bullish
15 minBullish
5 minExpanding
Daily trend turns up above $2.35
Key levels
Resistance$1.08
Resistance$0.96
Support$0.85
Support$0.77
Latest news & SEC filings
EarningsAllarity Therapeutics Sets Date for Q3 2026 Earnings Release
LegalAllarity Therapeutics reaches settlement agreement with Novartis
LegalAllarity Therapeutics resolves $4.9M Novartis obligation with $1M payment
SEC FilingAllarity Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All ALLR news →About Allarity Therapeutics
Allarity Therapeutics is a clinical-stage pharmaceutical company developing anti-cancer treatments. Its lead candidate, stenoparib, is an oral dual inhibitor of PARP and tankyrase enzymes, under study for ovarian cancer and combined with temozolomide in small cell lung cancer. The company also develops a gene-expression companion diagnostic, Drug Response Predictor, intended to pick out patients whose tumors are expected to answer a given cancer therapy. It operates in the United States and licenses its candidate from Eisai.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
Allarity Therapeutics, Inc. (ALLR)
What Is the Price Target for ALLR?
SEPT Low Target
$10.25
SEPT Mid Target
$10.25
SEPT High Target
$10.25
Analyst Consensus
$10.25
Is ALLR a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALLR.
Start Free Trial →Is ALLR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$10.25
7
Moat Score
NONE
4/9
Piotroski Score
-10.6
Altman Z-Score
What Is Smart Money Doing with ALLR?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Graff Jeremy R. | officer | Buy | 39,494 | - | Sep 30, 2026 |
| Graff Jeremy R. | officer | Sale | 14,613 | $14K | Sep 30, 2026 |
| Graff Jeremy R. | officer | Buy | 48,147 | - | Jan 22, 2026 |
| Graff Jeremy R. | officer | Sale | 17,814 | $21K | Jan 22, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ALLR Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
16.0%
Revenue Trend
UNKNOWN
Dark Pool Trades for ALLR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ALLR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:43:40 | $0.97 | 14,111 | $$14K | BUY |
| 20:34:51 | $0.90 | 2,000 | $$2K | SELL |
| 20:20:09 | $0.90 | 3,079 | $$3K | SELL |
| 19:57:58 | $0.89 | 1,000 | $$893 | SELL |
| 19:56:44 | $0.89 | 1,000 | $$893 | BUY |
5 dark pool trades shown · $$20K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Allarity Therapeutics, Inc. (ALLR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ALLR — frequently asked questions
What is ALLR stock price today?
Allarity Therapeutics, Inc. (ALLR) is at $0.91, down 2.30% (-$0.02) at the Nov 12, 2026 close.
Why is ALLR stock moving today?
Latest ALLR news — Nov 5, 2026: Allarity Therapeutics Sets Date for Q3 2026 Earnings Release · Nov 2, 2026: Allarity Therapeutics reaches settlement agreement with Novartis
What is the ALLR price target?
The average analyst price target for ALLR is $10.25, ranging from $10 to $10, based on 1 analysts. Latest: Ascendiant Capital maintains on Jun 8, 2026.
What do analysts rate ALLR?
Analyst ratings for ALLR: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did ALLR beat earnings?
ALLR last reported on Aug 14, 2026: EPS -$0.21 vs -$0.25 expected — a beat of 16.0%.
Does ALLR pay a dividend?
ALLR does not currently pay a dividend.
What are ALLR support and resistance levels?
Support: $0.85, $0.77, $0.68. Resistance: $0.96, $1.08, $1.18.
What are insiders doing with ALLR?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ALLR?
Nov 5, 2026: Allarity Therapeutics Sets Date for Q3 2026 Earnings Release · Nov 2, 2026: Allarity Therapeutics reaches settlement agreement with Novartis · Nov 2, 2026: Allarity Therapeutics resolves $4.9M Novartis obligation with $1M payment